BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

curasan AG (DX:CUR) Signs Sales Agreement with Stryker Corporation  (SYK)


2/9/2011 9:40:44 AM

Kleinostheim, Germany, 9 February 2011 – curasan AG, listed in the General Standard of the German Stock Exchange (ISIN: DE 000 549 453 8), has signed an agreement with Stryker S.A., Montreux, Switzerland, to sell and market bone replacement and regeneration materials for different orthopedic indications.

Starting summer 2011, Stryker anticipates launching the products in selected European countries to be potentially followed by further target markets.

"Partnering with Stryker, a powerful global leader with experience in biologicals and biomaterials, opens up the highest-volume market segment for us, namely, orthopedics", stated curasan's CEO, Hans Dieter Rössler.

David Halliday, VP Spine, Biotech CMF with responsibility for these product lines across Europe similarly expressed his satisfaction with the new partnership: “Once Stryker Europe decided to commit to focusing its sales efforts on the high-growth biomaterials market, the joint venture with curasan was an excellent strategic match."

The two corporations are planning a long-term collaboration and the possible inclusion of future pipeline products from curasan AG in the agreement.

About curasan:

Exchange listed curasan AG (ISIN: DE 000 549 453 8) is one of the leading firms in the field of regenerative medicine especially in bone and tissue regeneration. In addition to the synthetic Cerasorb® bone substitution and regeneration material, the company has developed a future-oriented product pipeline, which will be ready for market rollout within the next few years via well-positioned contractual partners in various market segments. www.curasan.com

About Stryker:

Stryker S.A. is the European Division of Stryker Corporation (NYSE:SYK), one of the world’s leading medical technology companies and is dedicated to helping healthcare professionals perform their jobs more efficiently while enhancing patient care. The company provides innovative orthopaedic implants as well as state-of-the-art medical and surgical equipment to help people lead more active and more satisfying lives. For more information about Stryker, please visit www.stryker.com.

Press Contact:

curasan AG Andrea Weidner Tel. +49 (0)6027 40 900-51 Fax +49 (0)6027 40 900-39 andrea.weidner@curasan.de www.curasan.de

fr financial relations gmbh Jörn Gleisner Tel. +49 (0)69 95 90 83 20 Fax +49 (0)69 95 90 83 99 j.gleisner@finanical-relations.de



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES